ArticleOTO open
Late Recurrences Beyond Five Years in Salivary Adenoid Cystic Carcinoma: Implications for Long-Term Surveillance.
Article in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Salivary adenoid cystic carcinoma (ACC) is a rare head and neck malignancy with limited surveillance guidelines. ACC disease patterns are quite variable and unpredictable. Herein, we present an institutional retrospective review of salivary adenoid cystic carcinoma and discuss patterns and predictors of recurrence. Study Design: Retrospective cohort study. Setting: Single Quaternary Care Referral Center. Methods: We analyzed 102 adult patients with salivary gland adenoid cystic carcinoma between 1988 and 2019. Patient and tumor-related characteristics are summarized, and recurrence, survival, and metastatic site data are described. Results: Multivariable analysis showed that greater than 30% solid pathology was independently predictive of recurrence (HR 5.32, CI 2.23-12.66). Advanced stage disease (stages III and IV) was also predictive of recurrence (HR 3.77, CI 1.57-9.03). Nearly one-third of all patients experienced distant recurrence. Among patients experiencing distant recurrence, 29% were diagnosed with distant recurrence more than 5 years post-treatment. Conclusion: These data support long-term surveillance and clinical follow-up for patients with ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.